Q: What is Keytruda used for?

Keytruda is used to treat: melanoma non-small cell lung cancer head and neck squamous cell carcinoma and others

Q: How does Keytruda work?

The Role of the Immune System The immune system uses specialized cells called T-cells to find and destroy abnormal cells, including cancer. However, some cancer cells can produce proteins that trick the immune system into leaving them alone, allowing the cancer to grow and spread. Blocking the PD-1 Pathway Keytruda is a type of monoclonal antibody known as a PD-1 inhibitor. It targets a protein called programmed death receptor-1 (PD-1) located on the surface of T-cells. Many cancer cells use a related protein called PD-L1 to bind with PD-1, which sends a signal to the T-cell to stop its attack. By blocking the PD-1 receptor, Keytruda prevents cancer cells from sending this signal. This action helps the immune system's T-cells stay active so they can better detect and destroy the cancer cells. Immunotherapy vs. Chemotherapy Unlike traditional chemotherapy, which works by directly killing fast-growing cells, Keytruda is an immunotherapy. This means it focuses on strengthening the body's natural defenses to fight the disease. It may be used as a primary treatment or alongside other therapies like surgery or chemotherapy.

Q: What are the active ingredients in Keytruda?

The active ingredient in Keytruda is pembrolizumab .

Q: What are the side effects of Keytruda?

Common side effects of Keytruda may include: Fatigue Pruritus Rash and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Keytruda?

Keytruda belongs to the PD-1 inhibitor drug class.

Q: What is the dosage of Keytruda and how do I take it?

Administration Keytruda is given by a healthcare provider in a hospital or clinic setting. It is administered in one of two ways: Intravenous infusion: The medication is delivered into a vein through an IV line. This process usually takes about 30 minutes. Subcutaneous injection: In some cases, the medication may be injected under the skin. Frequency and Schedule The treatment schedule is determined by a doctor based on the specific condition being treated. It is commonly administered once every three weeks or once every six weeks. Your healthcare provider will decide how many treatment cycles are necessary and how long the therapy should continue. Missed Doses It is important to keep all scheduled appointments for treatment. If an appointment is missed, contact your healthcare provider immediately to reschedule the dose. Maintaining a consistent schedule is necessary for the medication to be effective.

Q: Is Keytruda safe during pregnancy and breastfeeding?

Pregnancy Keytruda can cause harm to a developing fetus. Based on how the medication works, it may interfere with the immune system's ability to maintain a pregnancy, which could lead to pregnancy loss or fetal death. Healthcare providers typically advise against starting this medication during pregnancy unless the potential benefit outweighs the risks. Individuals who can become pregnant should have a pregnancy test before starting treatment to ensure they are not pregnant. It is important to use effective contraception during treatment and for at least 4 months after the final dose of Keytruda. If a patient becomes pregnant while receiving this medication, they should notify their healthcare provider immediately. Breastfeeding It is currently unknown whether Keytruda passes into human breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 4 months following the last dose. Patients should discuss alternative feeding options with their healthcare team to ensure the safety of the infant.

Q: What forms and strengths does Keytruda come in?

Dosage Forms Keytruda is supplied as a solution for injection. It is available in the following formats: Intravenous Infusion: This form is a clear to slightly opalescent, colorless to pale yellow solution supplied in a single-dose vial. A healthcare professional dilutes this solution before administering it through an intravenous (IV) line. Subcutaneous Injection: A formulation containing pembrolizumab and berahyaluronidase alfa-pmph is available for injection under the skin (subcutaneously).

Q: What is the FDA approval status of Keytruda?

FDA Approval Status Keytruda is approved by the U.S. Food and Drug Administration (FDA) for the treatment of numerous types of advanced or metastatic cancers. It belongs to a class of drugs known as PD-1 inhibitors, which help the immune system detect and attack cancer cells. The medication is approved for use in both adult and pediatric patients for specific indications, often depending on whether the cancer expresses certain biomarkers or has progressed after other treatments. Recent Regulatory Actions Head and Neck Cancer: The FDA recently approved pembrolizumab for use before surgery (neoadjuvant) in combination with chemotherapy, and then continued as a single agent after surgery (adjuvant), for resectable locally advanced head and neck squamous cell carcinoma (HNSCC). Ovarian Cancer: Approval was granted for use in combination with paclitaxel for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Subcutaneous Administration: In addition to the standard intravenous (IV) formulation, the FDA approved a subcutaneous injection version (pembrolizumab and hyaluronidase-alfa-pmph) for several indications previously approved for the IV version. Safety Monitoring Keytruda is a prescription-only medication. While it does not currently have a boxed warning, it is subject to ongoing monitoring for immune-related adverse reactions, which are a known risk of this class of immunotherapy. There are no specific Risk Evaluation and Mitigation Strategy (REMS) programs currently required for its use beyond standard clinical monitoring and patient medication guides.

Question 1

What is Keytruda?

Accepted Answer

Keytruda is a monoclonal antibody that functions as a type of immunotherapy. It works by blocking a specific protein pathway, which helps the immune system better detect and destroy cancer cells.

This treatment is designed to enhance the body's natural defenses to fight various malignancies. It belongs to a class of drugs known as PD-1 inhibitors.

Question 2

What is Keytruda used for?

Accepted Answer

Keytruda is used to treat:

melanoma
non-small cell lung cancer
head and neck squamous cell carcinoma
and others

Question 3

How does Keytruda work?

Accepted Answer

The Role of the Immune System

The immune system uses specialized cells called T-cells to find and destroy abnormal cells, including cancer. However, some cancer cells can produce proteins that trick the immune system into leaving them alone, allowing the cancer to grow and spread.

Blocking the PD-1 Pathway

Keytruda is a type of monoclonal antibody known as a PD-1 inhibitor. It targets a protein called programmed death receptor-1 (PD-1) located on the surface of T-cells. Many cancer cells use a related protein called PD-L1 to bind with PD-1, which sends a signal to the T-cell to stop its attack.

By blocking the PD-1 receptor, Keytruda prevents cancer cells from sending this signal. This action helps the immune system's T-cells stay active so they can better detect and destroy the cancer cells.

Immunotherapy vs. Chemotherapy

Unlike traditional chemotherapy, which works by directly killing fast-growing cells, Keytruda is an immunotherapy. This means it focuses on strengthening the body's natural defenses to fight the disease. It may be used as a primary treatment or alongside other therapies like surgery or chemotherapy.

Question 4

What are the active ingredients in Keytruda?

Accepted Answer

The active ingredient in Keytruda is pembrolizumab.

Question 5

What are the side effects of Keytruda?

Accepted Answer

Common side effects of Keytruda may include:

Fatigue
Pruritus
Rash
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Keytruda?

Accepted Answer

Keytruda belongs to the PD-1 inhibitor drug class.

Question 7

What is the dosage of Keytruda and how do I take it?

Accepted Answer

Administration

Keytruda is given by a healthcare provider in a hospital or clinic setting. It is administered in one of two ways:

Intravenous infusion: The medication is delivered into a vein through an IV line. This process usually takes about 30 minutes.
Subcutaneous injection: In some cases, the medication may be injected under the skin.

Frequency and Schedule

The treatment schedule is determined by a doctor based on the specific condition being treated. It is commonly administered once every three weeks or once every six weeks. Your healthcare provider will decide how many treatment cycles are necessary and how long the therapy should continue.

Missed Doses

It is important to keep all scheduled appointments for treatment. If an appointment is missed, contact your healthcare provider immediately to reschedule the dose. Maintaining a consistent schedule is necessary for the medication to be effective.

Question 8

Is Keytruda safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Keytruda can cause harm to a developing fetus. Based on how the medication works, it may interfere with the immune system's ability to maintain a pregnancy, which could lead to pregnancy loss or fetal death. Healthcare providers typically advise against starting this medication during pregnancy unless the potential benefit outweighs the risks.

Individuals who can become pregnant should have a pregnancy test before starting treatment to ensure they are not pregnant. It is important to use effective contraception during treatment and for at least 4 months after the final dose of Keytruda. If a patient becomes pregnant while receiving this medication, they should notify their healthcare provider immediately.

Breastfeeding

It is currently unknown whether Keytruda passes into human breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 4 months following the last dose. Patients should discuss alternative feeding options with their healthcare team to ensure the safety of the infant.

Question 9

What forms and strengths does Keytruda come in?

Accepted Answer

Dosage Forms

Keytruda is supplied as a solution for injection. It is available in the following formats:

Intravenous Infusion: This form is a clear to slightly opalescent, colorless to pale yellow solution supplied in a single-dose vial. A healthcare professional dilutes this solution before administering it through an intravenous (IV) line.
Subcutaneous Injection: A formulation containing pembrolizumab and berahyaluronidase alfa-pmph is available for injection under the skin (subcutaneously).

Question 10

What is the FDA approval status of Keytruda?

Accepted Answer

FDA Approval Status

Keytruda is approved by the U.S. Food and Drug Administration (FDA) for the treatment of numerous types of advanced or metastatic cancers. It belongs to a class of drugs known as PD-1 inhibitors, which help the immune system detect and attack cancer cells. The medication is approved for use in both adult and pediatric patients for specific indications, often depending on whether the cancer expresses certain biomarkers or has progressed after other treatments.

Recent Regulatory Actions

Head and Neck Cancer: The FDA recently approved pembrolizumab for use before surgery (neoadjuvant) in combination with chemotherapy, and then continued as a single agent after surgery (adjuvant), for resectable locally advanced head and neck squamous cell carcinoma (HNSCC).
Ovarian Cancer: Approval was granted for use in combination with paclitaxel for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Subcutaneous Administration: In addition to the standard intravenous (IV) formulation, the FDA approved a subcutaneous injection version (pembrolizumab and hyaluronidase-alfa-pmph) for several indications previously approved for the IV version.

Safety Monitoring

Keytruda is a prescription-only medication. While it does not currently have a boxed warning, it is subject to ongoing monitoring for immune-related adverse reactions, which are a known risk of this class of immunotherapy. There are no specific Risk Evaluation and Mitigation Strategy (REMS) programs currently required for its use beyond standard clinical monitoring and patient medication guides.

Question 11

What should I know about Keytruda and cost?

Accepted Answer

Keytruda is a prescription medication that must be administered by a healthcare professional in a medical setting. Because it is not a drug patients can purchase and administer themselves, the total cost is often tied to the professional services and the facility where treatment occurs.

Factors Influencing Cost

Administration Method: Keytruda is typically delivered as an intravenous (IV) infusion. However, some versions are approved for administration as a subcutaneous injection. The method used may affect the overall cost of the procedure.
Treatment Schedule: The frequency of doses and the total duration of therapy are determined by the healthcare provider based on the specific condition being treated and how the patient responds to the medication.
Clinical Setting: The medication is given in hospitals, clinics, or infusion centers. Costs can vary based on the specific facility and the professional monitoring required during administration.

Patients should consult with their healthcare provider or insurance carrier to obtain specific pricing information and to understand their coverage options for this treatment.

Keytruda

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Keytruda

Hospitals.net Disclosure